Difference between revisions of "Deferiprone (Ferriprox)"
Jump to navigation
Jump to search
m (Text replacement - "[[File:" to "[[:File:") |
Warner-admin (talk | contribs) m (Text replacement - "please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [https://online.lexi.com/lco/action/login UpToDate Lexidrug], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information" to "please refer to your preferred pharmacopeias or the prescribing information") |
||
(2 intermediate revisions by the same user not shown) | |||
Line 1: | Line 1: | ||
==General information== | ==General information== | ||
− | Class/mechanism: Iron chelating agent; binds with ferric ions and forms neutral 3:1 (deferiprone:iron) complexes that are stable over a wide range of pH values. | + | Class/mechanism: Iron chelating agent; binds with ferric ions and forms neutral 3:1 (deferiprone:iron) complexes that are stable over a wide range of pH values. Deferiprone has higher binding affinity for iron than other metals such as copper, aluminum, and zinc.<ref name="insert">[http://www.ferriprox.com/us/pdf/ferriprox_full_pi.pdf Deferiprone (Ferriprox) package insert]</ref><ref>[[:File:Deferiprone.pdf | Deferiprone (Ferriprox) package insert (locally hosted backup)]]</ref><ref>[http://www.ferriprox.com Ferriprox manufacturer's website]</ref> |
<br>Route: PO | <br>Route: PO | ||
<br>Extravasation: n/a | <br>Extravasation: n/a | ||
− | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias | + | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias or the prescribing information.<ref name="insert"></ref> |
==Patient drug information== | ==Patient drug information== |
Latest revision as of 01:06, 29 June 2024
General information
Class/mechanism: Iron chelating agent; binds with ferric ions and forms neutral 3:1 (deferiprone:iron) complexes that are stable over a wide range of pH values. Deferiprone has higher binding affinity for iron than other metals such as copper, aluminum, and zinc.[1][2][3]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias or the prescribing information.[1]
Patient drug information
- Deferiprone (Ferriprox) package insert pages 9-12[1]
- Deferiprone (Ferriprox) patient drug information (UpToDate)[4]
Also known as
- Brand name: Ferriprox